Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Fate Therapeutics, Inc. (FATE) vs Immuneering Corporation (IMRX)

Fate Therapeutics, Inc. and Immuneering Corporation are both Biotechnology companies. Fate Therapeutics, Inc. and Immuneering Corporation are of similar size ($280.8M and $279.2M). Fate Therapeutics, Inc. grew revenue faster over the last twelve months: −23.4% against −84.8%. Immuneering Corporation has the higher net margin (0.00% vs −1,941.1%) and the lower return on invested capital (−97.1% vs 0.00%). Across the 16 metrics below, Immuneering Corporation leads on 9 and Fate Therapeutics, Inc. on 7.

Valuation

Metric FATE IMRX Biotechnology median
P/E n/m n/m 7.88
P/S 43.59 871.47 11.47
P/B 1.84 1.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 36.07 398.60 10.73
Earnings yield (44.68%) (24.36%) (28.84%)
Free cash flow yield (37.26%) (20.63%) (23.03%)

Profitability

Metric FATE IMRX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (2,058.08%) 0.00% 0.00%
Net margin (1,941.09%) 0.00% 0.00%
Free cash flow margin (1,624.06%) 0.00% 0.00%
Return on equity (60.75%) (52.15%) (57.72%)
Return on assets (39.89%) (47.31%) (49.22%)
Return on invested capital 0.00% (97.14%) 0.00%

Growth

Metric FATE IMRX Biotechnology median
Revenue growth (TTM) (23.36%) (84.76%) 5.64%
EPS growth (last fiscal year) 29.88% 37.75% —
Revenue growth, 5-year CAGR (26.71%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric FATE IMRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.85 19.47 4.73
Net debt to EBITDA 1.47 2.94 0.96

Dividend

Metric FATE IMRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric FATE IMRX Biotechnology median
Market cap 279.18m 280.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack